{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'lab (e.g. Decipher [GenomeDX Biosciences, San Diego, CA] and/or Oncotype DX', 'Prostate Cancer Assay [Genomic Health, Inc., Redwood City, CA]).', '7.4. Safety', 'Safety will be evaluated based on the incidence, severity, duration, causality,', \"seriousness, and type of adverse events (AEs), and changes in the patient's physical\", 'examination, vital signs, and clinical laboratory results. Investigators will use the NCI', 'CTC version 4.03 (published 14 June 2010) to assess the severity of AEs and toxicities', '(see Appendix B). For safety considerations specific to apalutamide see section 8.1 of', 'the protocol.', '44', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '8.', '8.1.', '8.1.1.', '8.1.2.', '45', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '46', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}